Nueva Terapia Génica Supera la Resistencia Inmunológica en Pacientes con Exposición Previa

Gene therapy holds immense promise for treating age-related diseases and extending healthspan, but immune responses against delivery vectors often prevent repeated treatments or limit effectiveness in previously exposed patients. This groundbreaking study addresses this critical limitation.

Researchers tested whether co-delivering immune checkpoint ligands PD-L1 and PD-L2 could protect gene therapy from immune clearance. They used adeno-associated virus vectors to deliver therapeutic genes alongside these protective proteins in both naive mice and those pre-immunized against the delivery system.

The results were remarkable. In pre-immunized mice, co-delivery of PD-L1 increased therapeutic protein production by 33-fold at 5 weeks and 31-fold at 12 weeks compared to standard gene therapy. PD-L2 showed similar but slightly less dramatic improvements. Treated muscles also showed reduced immune cell infiltration, indicating better protection of gene-modified cells.

For longevity and health optimization, this breakthrough could enable repeated gene therapy treatments for age-related conditions, personalized medicine approaches, and therapeutic interventions in people with pre-existing immunity. Potential applications include treatments for cardiovascular disease, muscle wasting, metabolic disorders, and other age-related conditions.

However, this remains early-stage research conducted only in mice. Human immune systems are more complex, and long-term safety of immune checkpoint manipulation requires careful evaluation. The approach also involves modifying local immune responses, which could theoretically affect cancer surveillance, though no adverse effects were observed in this study.